Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06947941
PHASE3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Sponsor: Bristol-Myers Squibb
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease
Key Details
Gender
All
Age Range
55 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
1046
Start Date
2025-07-31
Completion Date
2027-10-25
Last Updated
2025-04-27
Healthy Volunteers
No
Conditions
Interventions
DRUG
KarXT
Specified dose on specified days
DRUG
KarX-EC
Specified dose on specified days
DRUG
KarXT + KarX-EC Arm Matching Placebo
Specified dose on specified days